Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 18/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14984949 | 1.00 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL23710407 | 1.00 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL6883791 | 1.00 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL21582882 | 1.00 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL6883789 | 1.00 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL13799962 | 0.94 | METAP2 (0.78) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL19880170 | 0.94 | METAP2 (0.82) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL18458208 | 0.94 | METAP2 (0.82) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL21017027 | 0.93 | METAP2 (0.76) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL21880698 | 0.93 | METAP2 (0.76) | METAP2ABCB11LMNAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170326135-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170258925-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9757373-B2 | MetAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9750737-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9730955-B2 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170196830-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | SYNDEVRX, INC. | 2017-07-13 | — | — | US | disclosed |
| US-9585909-B2 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258925-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | METAP2 1/4885ABCB11 226/4885LMNA 3918/4885 |
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | METAP2 1/4885ABCB11 2461/4885LMNA 2972/4885 |
| US-20170326135-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | METAP2 1/4885ABCB11 2461/4885LMNA 2972/4885 |
| US-20170196830-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | PCK2, GOT2, PC | METAP2 40/4885ABCB11 3114/4885LMNA 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.